Coya Therapeutics

Coya Therapeutics is a clinical-stage biotechnology company developing disruptive, first-in-class approaches to target diseases using autologous regulatory T cells (Tregs) and Treg-derived exosome therapies, initially focusing on neurodegenerative and autoimmune diseases. Dysfunctional Tregs underlie neurodegenerative and autoimmune diseases, and we are leveraging these groundbreaking discoveries from the Stanley Appel MD laboratory to deliver new therapeutic options through our TAI™ platform (Anti-inflammatory Tregs). TAI™ involves transforming dysfunctional Tregs into "Super Tregs," enabling potent immunosuppression and neuroprotective functions, aiming to address significant unmet medical needs for patients with Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Frontotemporal Dementia (FTD), and other neurodegenerative and autoimmune diseases.